Abstract: Described herein are antimicrobial formulations or compositions comprising an N-halogenated or N,N-dihalogenated amine compound and a saccharide-based gelling agent. Methods of using such formulations, including a method of preventing or treating an infection caused by a bacterial, a microbial, a sporal, a fungal or a viral activity, are also disclosed.

Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are described. Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Abstract: The present invention provides for a gain control circuit (10) and method for providing gain control of a variable amplification circuit (16) using a pilot signal. A pilot signal is added to the received signal. The pilot signal has at least a minimum signal level which when added to the signal received insures the sampled input signal has a level above the point where offset or low power errors are experienced. Preferably the pilot signal will be a sinusoidal signal having a frequency within the operational bandwidth of the amplifier (16), but outside the frequency range of the input signal.

Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.

Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.

Abstract: 2-Chloromethyl-3-(tri-O-benzyl-.alpha.-L-C-fucopyranoside)-1-propene and methods of making the same are described. Methods of combining this substituted fucopyranose with triterpenoid acid also are described.

Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.

Abstract: This invention relates generally to the field of medicinal chemistry, and more specifically to derivatives of a subclass of triterpenoid acids that have multi-medicament properties, that is derivatives of the lupane, betulinic acid, formulations containing such, and their use to prevent or treat certain diseases, and preferably to derivatives or analogues of betulinic acid, that have the following structural formula (1): ##STR1## wherein: Y is OR.sup.1, NR.sup.1.sub.2, O.sup.- M.sup.1 ;R.sup.1 is H, LOWER ALKYL,M.sup.1 is Na.sup.+, K.sup.+, Mg.sup.++, Ca.sup.++ ions;each R.sup.2 is independently CH.sub.2 OR.sub.1 or CH.sub.3 ;each R.sup.3 is independently H, CH.sub.3, lower alkyl, COY, CH.sub.2 OH, CH.sub.2 OCH.sub.2 CH=CH.sub.2, CH.sub.2 OSO.sub.3.sup.- M.sup.1 ;each Z is independently NHR.sup.1.sub.2, NR.sup.1 Ac, NR.sup.1 Bz, H, OCH.sub.3, lower alkyl, OH, OSO.sub.3.sup.- M.sup.1, OCH.sub.2 CH=CH.sub.2, OCH.sub.2 CO.sub.2 H or O-glucoside;each X is independently O, S, NR.sup.1 or NR.sub.2.sup.